Treść książki

Przejdź do opcji czytnikaPrzejdź do nawigacjiPrzejdź do informacjiPrzejdź do stopki
9.RobsonE.J.D.,HeS.J.,EcclesM.R.APANoramaofPAXgenesincanceranddevelopment.
NatRevCancer.2006;6:52-62,https://doi.org/10.1038/NRC1778.
10.QuickC.M.,LauryA.R.,MonteN.M.,MutterG.L.UtilityofPAX2asamarkerfordiagnosis
ofendometrialintraepithelialneoplasia.AmJClinPathol.2012;138:678-684,https://doi.
org/10.1309/AJCP8OMLT7KDWLMF
.
11.StambolicV.,TsaoM.S.,MacphersonD.iwsp.Highincidenceofbreastandendometrial
neoplasiaresemblinghumanCowdensyndromeinpten(+/-)mice.CancerRes.2000;60:
3605-3611,
12.DaikokuT.,HirotaY.,TranguchS.iwsp.ConditionallossofuterinePtenunfailinglyand
rapidlyinducesendometrialcancerinmice.CancerRes.2008;68:5619-5627,https://doi.
org/10.1158/0008-5472.CAN-08-1274.
13.MutterG.L.,LinM.C.,FitzgeraldJ.T.iwsp.AlteredPTENexpressionasadiagnosticmarker
fortheearliestendometrialprecancers.JNatlCancerInst.2000;92:924-931,https://doi.
org/10.1093/jnci/92.11.924.
14.PilarskiR.Cowdensyndrome:Acriticalreviewoftheclinicalliterature.JGenetCouns.
2009;18:13-27,https://doi.org/10.1007/S10897-008-9187-7.
15.AyhanA.,MaoT.L.,SuryoRahmantoY
.iwsp.Increasedproliferationinatypicalhyper-
plasia/endometrioidintraepithelialneoplasiaoftheendometriumwithconcurrentinactiva-
tionofARID1AandPTENtumoursuppressors.JPatholClinRes.2015;1:186,https://doi.
org/10.1002/CJP2.22.
16.ShangS.,HuaF.,HuZ.W
.Teregulationofβ-cateninactivityandfunctionincancer:the-
rapeuticopportunities.Oncotarget.2017;8:33972,https://doi.org/10.18632/ONCOTAR-
GET.15687.
17.NorimatsuY.,MoriyaT.,KobayashiT.K.iwsp.ImmunohistochemicalexpressionofPTEN
andβ-cateninforendometrialintraepithelialneoplasiainJapanesewomen.AnnDiagn
Pathol.2007;11:103-108,https://doi.org/10.1016/j.anndiagpath.2006.06.009.
18.XiongY.,XiongY.Y.,ZhouY.F
.Expressionandsignificanceofβ-catenin,Glut-1andPTEN
inproliferativeendometrium,endometrialintraepithelialneoplasiaandendometrioid
adenocarcinoma.EurJGynaecolOncol.2010;31:160-164,
19.YenT.T.,WangT.L.,FaderA.N.iwsp.Molecularclassificationandemergingtargetedthe-
rapyinendometrialcancer.IntJGynecolPathol.2020;39:26-35,https://doi.org/10.1097/
PGP.0000000000000585.
20.AlexaM.,HasenburgA.,BattistaM.J.Tetcgamolecularclassificationofendometrial
canceranditspossibleimpactonadjuvanttreatmentdecisions.Cancers(Basel).2021;13,
https://doi.org/10.3390/cancers13061478.
21.MissaouiN.,BoukhariN.,LimamS.iwsp.Utilityoftheimmunohistochemicalanalysis
ofDNAmismatch-repairproteinsinendometrialhyperplasia.ActaHistochem.2020;122,
https://doi.org/10.1016/J.ACTHIS.2020.151505.
22.DoghriR.,HoucineY.,BoujelbèneN.iwsp.Mismatchrepairdeficiencyinendometrial
cancer:Immunohistochemistrystainingandclinicalimplications.ApplImmunohistochem
MolMorpholAIMM.2019;27:678-682,https://doi.org/10.1097/PAI.0000000000000641.
23.MakkerV.,ColomboN.,CasadoHerráezA.iwsp.LenvatinibplusPembrolizumabfor
AdvancedEndometrialCancer.NEnglJMed.2022;386:437-448,https://doi.org/10.1056/
NEJMOA2108330.
16
2.Etiopatogenezarakaendometrium